Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trimetazidine in HFpEF
NL-OMON48659Phase 2Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of trimetazidine in heart failure with preserved ejection fraction (HFpEF) (2 arms), sponsored by Vrije University Medical Center. Primary endpoint: Exercise pulmonary capillary wedge pressure. Started Apr 2019; status: active, not recruiting.
02
Drugs
trimetazidine
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NL-OMON48659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48659.